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Abstract The dual-specificity tyrosine-phosphorylation-
regulated kinase, DYRK1B, is expressed de novo during
myogenesis, amplified or mutated in certain cancers and
mutated in familial cases of metabolic syndrome.
DYRK1B is activated by cis auto-phosphorylation on tyr-
osine-273 (Y273) within the activation loop during
translation but few other DYRK1B phosphorylation sites
have been characterised to date. Here, we demonstrate that
DYRK1B also undergoes trans-autophosphorylation on
serine-421 (S421) in vitro and in cells and that this site
contributes to DYRK1B kinase activity. Whilst a
DYRK1BS421A mutant was completely defective for
p-S421 in cells, DYRK1B inhibitors caused only a partial
loss of p-S421 suggesting the existence of an additional
kinase that could also phosphorylate DYRK1B S421.
Indeed, a catalytically inactive DYRK1BD239A mutant
exhibited very low levels of p-S421 in cells but this was
increased by KRASG12V. In addition, selective activation of
the RAF-MEK1/2-ERK1/2 signalling pathway rapidly
increased p-S421 in cells whereas activation of the stress
kinases JNK or p38 could not. S421 resides within a Ser-
Pro phosphoacceptor motif that is typical for ERK1/2 and
recombinant ERK2 phosphorylated DYRK1B at S421
in vitro. Our results show that DYRK1B is a novel ERK2
substrate, uncovering new links between two kinases
involved in cell fate decisions. Finally, we show that
DYRK1B mutants that have recently been described in
cancer and metabolic syndrome exhibit normal or reduced
intrinsic kinase activity.
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kinases (DYRKs) are an evolutionarily conserved family of
protein kinases that are found within the CMGC group
(CDK, MAPK, GSK and CLK families) of the eukaryote
kinome [1–4]. The mammalian DYRKs are divided into
class I (DYRK1A and DYRK1B) and class II (DYRK2,
DYRK3 and DYRK4) based on sequence homologies. The
DYRKs require phosphorylation of the second tyrosine in
the characteristic tyrosine-X-tyrosine (Y–X–Y) motif
within their activation loop for kinase activity [5, 6]. In
contrast to many other kinases, this activation loop phos-
phorylation is not catalysed by an upstream, ‘activating
kinase’ but occurs during translation when DYRKs
undergo intramolecular cis-autophosphorylation on tyr-
osine [7]. As co-translational activation loop tyrosine
phosphorylation is a one-time-only event, it was proposed
that once synthesised, the mature DYRKs lose tyrosine
kinase activity and phosphorylate substrates exclusively on
serine or threonine residues. However, recent studies have
demonstrated that mature DYRK1A retains the ability to
autophosphorylate on other tyrosine residues outside the
activation loop [8]. Regardless, substrate phosphorylation
appears to occur exclusively on serine or threonine, usually
within a proline-directed context (pS-P or pT-P) [9, 10].
The DYRKs have roles in controlling transcription, mRNA
splicing, cell cycle progression, survival and differentiation
[2, 3]. For example, loss of a single copy of Dyrk1a in mice
leads to increased apoptosis and decreased brain size in
mice [11]. In addition, the DYRK1A gene is situated in the
Down’s syndrome (DS) critical region on chromosome 21
(21q22.1–22.3), is over-expressed in both foetal and adult
brains of DS individuals [12] and is thought to contribute to
the clinical features of Down’s syndrome [13–15]. Indeed,
Dyrk1a is the triplicated gene that causes decreased nuclear
Cyclin D1 levels and early cortical neurogenic defects in a
mouse model of DS [16]. Together, these studies empha-
sise the importance of DYRK1A gene dosage and activity.
As a result of their co-translational activation loop
phosphorylation the DYRKs are active once translated,
however, there is growing evidence that some DYRKs are
subject to additional post-translational modification and
regulation. Autophosphorylation of DYRK1A allows
binding of 14-3-3, which promotes DYRK1A catalytic
activity [17, 18]. In C. elegans, the DYRK homologue,
minibrain kinase-2, is activated during oocyte maturation
by cyclin-dependent kinase-1 (CDK1)-dependent phos-
phorylation of serine 68, a residue outside of the kinase
domain that is required for full activity in vivo [19].
DYRK2 is phosphorylated at T33 and S369 (numbering
corresponding to the short form of DYRK2) by the Ataxia
telangiectasia mutated kinase (ATM) in response to geno-
toxic stress; this inhibits the ubiquitination of DYRK2,
which can then phosphorylate S46 of the tumour suppres-
sor p53 [20]. Finally, mass spectrometry of human DYRK4
expressed in HEK293 cells has identified phosphorylated
Ser and Thr residues, indicating that DYRK4 is phospho-
rylated by other cellular protein kinases [21].
DYRK1B is implicated in promoting differentiation in
several models: for example, it is expressed de novo during
myogenesis [22] and undergoes differential splicing during
adipogenesis [23]. Indeed, DYRK1B can promote cell
cycle arrest by multiple mechanisms including promoting
cyclin D1 (CCND1) degradation [24, 25] by direct phos-
phorylation at T286 [25] and increasing the expression of
the cyclin-dependent kinase inhibitors p21CIP1 and p27KIP1
[24, 25]. Mutations in DYRK1B have been reported in an
inherited form of metabolic syndrome associated with
early-onset coronary artery disease, obesity, hypertension
and diabetes [26]. In addition, DYRK1B is amplified [27,
28] and mutated [29] in certain cancers and has been
reported to promote cell survival [30–32]. Despite this, less
is known about the post-translational regulation of
DYRK1B. It has been suggested that oncogenic KRAS
stimulates DYRK1B kinase activity [33] and that
DYRK1B is a downstream effector of KRAS [34] but the
molecular details of this regulation remain unclear.
There is growing interest in inhibiting DYRKs and
several small molecule inhibitors of the class I DYRKs
have been described including DYRK1B-selective inhibi-
tors such as AZ191 [25] and dual 1A/1B inhibitors such as
INDY [35] and Harmine [36]. These inhibitors are selec-
tive for the Ser/Thr kinase activity of the mature DYRKs
[25, 36], only inhibiting the Tyr kinase activity at very high
doses, and are, therefore, useful in helping to define DYRK
substrates and DYRK functions. To progress our interest in
DYRK1B, we sought to identify DYRK1B autophospho-
rylation sites that were dependent on the Ser/Thr kinase
activity of mature DYRK1B, since these might serve as
biomarkers for DYRK1B activity and DYRK1B inhibitors.
Here, we identify serine-421 (S421) as a site of DYRK1B
trans-autophosphorylation that is inhibited by DYRK1B
Ser/Thr kinase inhibitors and contributes to DYRK1B
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kinase activity. Remarkably, S421 is also phosphorylated
in a MEK1/2-ERK1/2-dependent fashion in cells and by
ERK2 in vitro, defining DYRK1B as a new substrate of
ERK2 and providing a link between between two kinases
involved in cell fate decisions. Finally, we show that
mutations in DYRK1B that are found in cancer or meta-
bolic syndrome either inhibit or are without effect on
DYRK1B kinase activity. These results provide new
insights into the regulation and role of DYRK1B.
Materials and methods
Materials
AZ191 (DYRK1B inhibitor) and selumetinib (AZD6244/
ARRY-142886, an allosteric MEK1/2 inhibitor) were
provided by AstraZeneca, Alderley Park, Macclesfield,
UK. Palbociclib (PD-0332991, CDK4/6 inhibtor) and
SCH772984 (ERK1/2 inhibitor) were from Selleck.
Horseradish peroxidase-conjugated secondary antibodies
were from Bio-Rad, and detection was with the enhanced
chemiluminescence (ECL) system (GE Healthcare). All
other reagents were from Sigma.
Antibodies
DYRK1B antibodies produced in rabbits using the
immunogen CGLRGVPQSTAASS for the Western blot
antibody and MAVPPGHGPFSGC for the antibody used
for immunoprecipitation assays were provided by Astra-
Zeneca (Alderley Park, Macclesfield, UK) and were
described previously. The p-S421-DYRK1B antibody, also
from AstraZeneca, was produced in rabbits immunised
with the BSA conjugated phospho-peptide ac-CGE-
PAARI(P)SPLGALQHG-nh2, prepared using standard
procedures [37]. Antibodies specific for p-T202/Y204-
ERK1/2 (9106), ERK1/2 (4695), p-T180/Y182-p38 (9211),
p-T183/Y185-JNK (9251), pT286-cyclin D1 (2921),
p-S33/S37/T41-b Catenin (9561) were from Cell Signaling
Technologies; ERK1 (610031), HSP90 (610418) and b-
Catenin (610153) were from BD Biosciences, b-actin
(A5441) was from Sigma; GFP (11814460001) was from
Roche; cyclin D1 (CC12) and Ras (OP40) were from
Calbiochem. JNK1/3 (sc474) and ERK2 (sc154) were from
Santa Cruz Biotechnology; Flag (MAB3118) was from
Millipore; p38 antibody was provided by the Babraham
Institute Monoclonal Antibody Facility.
Plasmids
For the mass spectrometry experiments, DYRK1B sequence
(Swissprot Q9Y463; Embl AF205861) was ordered from
Geneart with a c-terminal myc-tag and subcloned into
pcDNA3. pcDNA3-DYRK1B was mutated by site-directed
mutagenesis to generate catalytically inactiveY271F/Y273F
and K140R constructs. For other experiments DYRK1Bwas
amplified by PCR from pOTB7-DYRK1B (from Mam-
malian Gene Collection) and subcloned into pCMV-Tag2B
and pEGFP-C3. pCMV-Tag2B-DYRK1B was mutated by
site-directed mutagenesis to generate to catalytically inac-
tive DYRK1B (D239A). pCGN-KRAS12V was from
Adrienne Cox, Department of Pharmacology, University of
North Carolina at Chapel Hill. The sequences of all oligos
used are available upon request.
Analysis of in vitro autophosphorylation
of recombinant DYRK1B by mass spectrometry
Recombinant DYRK1B expressed in insect cells (Carna
Biosciences) was allowed to autophosphorylate in the
presence of ATP. The protein was then resolved on a
Novex gel followed by Coomassie staining. The Coo-
massie bands were reduced with DTT (Sigma), alkylated
with iodoacetamide (Sigma), followed by digestion with:
trypsin only; AspN and trypsin; chymotrypsin only; chy-
motrypsin and trypsin (all enzymes supplied by Roche).
The resultant peptides were extracted and concentrated.
The sample was chromatographed using the Dionex U3000
nanoflow chromatography system (ThermoFisher), the
outlet flow ran directly into the Qstar Elite mass spec-
trometer (ABSciex) for analysis via the nanoflow probe at a
flow rate of 300 nl/min. A 40 min reversed phase gradient
was run using a 300 lm i.d. 9 5 mm C18 PepMap (Dionex
ThermoFisher) trapping pre-column and a 75 lm i.d. 9
15 cm C18 ACE analytical column (Hichrom). The Qstar
collected data in positive ion mode and an auto-switching
setup was initiated with automatic precursor selection
based on peak intensity and charge state. The subsequent
data files generated were searched against the Swissprot
database, using the Mascot Daemon software. The searches
were then manually verified to confirm phosphorylation
sites. From the MSMS data of the phosphorylated and non-
phosphorylated peptides, the parent mass and key daughter
ion masses were used to generate an MRM (multiple
reaction monitoring) method on the 4000 Qtrap mass
spectrometer (ABSciex).
Analysis of DYRK1B autophosphorylation
in recombinant enzyme and cells by mass
spectrometry using MRM
Recombinant DYRK1B enzyme was incubated with ATP
in the presence or absence of 10 lM AZ’294 (an early
DYRK1B HTS hit, with an IC50 of\ 0.03 lM in an
in vitro enzyme assay), and run on a Novex gel followed by
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Coomassie Staining. Reduction, alkylation and digestion
with trypsin was carried out as above. Wild-type or mutant
myc-DYRK1B proteins were transiently expressed in
COS-1 cells. DYRK1B proteins were enriched from whole
cell lysates using anti-myc antibody, after treatment with
10 lM AZ’294 or 0.1 % DMSO for 2 h. Immuno-com-
plexes were digested with trypsin prior to nano-liquid
chromatography mass spectrometry. MRM was performed
on the 4000 Qtrap mass spectrometer using the previously
generated method from the recombinant analysis. The
sample was chromatographed using the Dionex U3000
nanoflow chromatography system (ThermoFisher) the
outlet flow ran directly into the 4000 Qtrap for analysis via
the nanoflow probe at a flow rate of 700 nl/min. A 5 min
reversed phase gradient was run using a 300 lm i.d. 9
5 mm C18 PepMap (Dionex ThermoFisher) trapping pre-
column and a 75 lm i.d. 9 15 cm C18 ACE analytical
column. The column was then equilibrated culminating in a
12.5 min run time per sample. The non-phosphorylated and
phosphorylated masses of the pS421 containing tryptic
peptide were monitored. Peak quantification was estab-
lished using ABSciex software, this was manually verified
and exported to Excel for further data analysis.
Cells and cell culture
Cell culture reagents were purchased from Invitrogen.
HEK293 cells were maintained in DMEM supplemented
with 10 % FBS, 2 mM L-glutamine, 100 Uml-1 penicillin,
0.1 lgml-1 streptomycin. HR1 and HM3 cells were
maintained in HEK293 media supplemented with G418
equivalent to 400 lgml-1 neomycin (HR1) or 2 lgml-1
Puromycin (HM3) to maintain stable clone selection.
HD1B cells were maintained in HEK293 media supple-
mented with 10lgml-1 Blasticidin, 100 lgml-1 Zeocin
and G418 equivalent to 400 lgml-1 neomycin. Cells were
routinely passaged before 80 % confluency.
Preparation of cell extracts and Western blotting
Cells were lysed in ice-cold TG lysis buffer, assayed for
protein content and fractionated by SDS-PAGE as descri-
bed previously [38]. SDS-PAGE gels were transferred to
Immobilon P membranes (Millipore), which were blocked
in 0.1 % (v/v) Tween-20–TBS (tris-buffered saline) con-
taining 5 % (w/v) powdered milk and probed with the
indicated antibodies. Immune complexes were visualised
with the ECL system (GE Healthcare).
In vitro DYRK kinase assay
FLAG-DYRK1B [wild-type (WT), kinase-dead (KD,
D239A) or S421A (SA)] were immunoprecipitated from
whole cell lysates with anti-FLAG antibodies and then
assayed for kinase activity by incubating with 50 lM
Woodtide with two additional lysines attached to the
N terminus to allow it to bind to P81 paper (KKISGRL-
SPIMTEQ), 50 mM Tris/HCl, pH 7.5, 0.1 mM EGTA,
0.1 % (v/v) 2-mercaptoethanol, 10 mM MgCl2, 0.1 mM
[c-32P]ATP in a total volume of 50 ll for 20 min at 30 C
as described previously [7]. For each experiment, a single
IP was used to generate three technical replicates of 32P
incorporation in the in vitro assay in addition to quantifying
the amount of DYRK1B present by immunoblot. In other
experiments (Fig. 2b) FLAG-DYRK1B (kinase-dead;
D239A or K140 M) was immunoprecipitated from whole
cell lysates with anti-FLAG antibodies and used as a sus-
bstrate for GST-DYRK1B (Full length recombinant human
DYRK1B expressed in insect cells, Invitrogen PV4649).
Each 50 ll reaction contained 0.3 lg GST-DYRK1B and
10 ll kinase-dead DYRK1B substrate beads in a buffer
containing 50 mM Tris/HCl, pH 7.5, 0.1 mM EGTA,
0.1 % (v/v) 2-mercaptoethanol, 10 mM MgCl2, 0.1 mM
ATP. Reactions were incubated at 30 C for 50 min and
terminated by the addition of 20 ll 4 9 Laemmli Buffer
and heating at 95 C for 5 min. Reactions were fraction-
ated by SDS-PAGE, transferred onto PVDF membrane and
immunoblotted with the indicated antibodies.
In vitro ERK2 kinase assay
FLAG-DYRK1B (WT or S421A) or empty vector was
expressed in HEK293 cells for 24 h in the presence of
10 lM AZ191. FLAG-DYRK1B was isolated from whole
cell extracts by anti-flag immunoprecipitation and used as a
substrate in an ERK2 in vitro kinase assay. Each 50 ll
reaction contained 0.4 lg GST-ERK2 (Sigma-Aldrich,
E1283), 20 ll substrate beads and 50 lM [c-32P]ATP
(2.5 lCi per reaction) in a buffer containing 7 mM MOPS
(pH 7.2), 3.5 mM glycerol 2-phosphate, 7 mM MgCl2,
1.4 mM EGTA, 0.56 mM EDTA and 0.07 mM DTT.
Reactions were incubated at 30 C for 1 h and terminated
by the addition of 17 ll 49 Laemmli Buffer and heating at
95 C for 5 min. Reactions were separated by SDS-PAGE,
transferred onto PVDF membrane and 32P incorporation
was detected by autorad followed by probing with the
indicated antibodies.
DYRK1B siRNA
DYRK1B siRNA (Thermo siGENOME, MQ-004806-01-
0002) and GFP siRNA (Qiagen 1027310) were dissolved in
nuclease-free water to generate stock solutions of 20 lM
and used at a final concentration of 30 nM. For each well
of a six well plate, 5 ll of Lipofectamine 2000 was diluted
in 250 ll OptiMEM and incubated at room temperature for
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5 min. siRNA were diluted in 250 ll OptiMEM prior to the
addition of 250 ll of the Lipofectamine-OptiMEM solu-
tion. The transfection mixes were incubated at room
temperature for 20 min to allow the formation of siRNA
complexes. Cells were seeded the previous day in Pen/
Strep-free medium to achieve a confluency of 50 % on the
day of transfection. 500 ll of the transfection solution was
added to each well of the tissue culture plate and the cells
were incubated 37 C in a humidified incubator with 5 %
(v/v) CO2 for 16 h. After this 16 h, the medium was
changed to fresh Pen/Strep-free media containing DMSO
or 1 lM Selumetinib. The cells were incubated for a fur-
ther 48 h at 37 C in a humidified incubator with 5 % (v/v)
CO2 prior to harvesting.
Analysis of cell cycle distribution and cell death
Cell cycle distribution (G1, S, G2/M) and the fraction of
dead cells (those with sub-G1 DNA content) was assessed
by staining fixed cells with propidium iodide followed by
flow cytometry as described previously [38, 39].
Results
Identification of S421 as a novel DYRK1B
autophosphorylation site that promotes kinase
activity
When expressed in cells catalytically inactive DYRK1B
exhibits enhanced migration on SDS-PAGE gels compared
to wild-type suggesting that DYRK1B normally undergoes
autophosphorylation in vivo [25]. Activation of DYRK1B
requires auto-phosphorylation in cis at tyrosine 273 (Y273)
within the activation loop. However, once translation is
complete mature DYRK1B phosphorylates substrates on
Ser/Thr residues in trans. We wished to develop an assay to
monitor the kinase activity of mature DYRK1B in cells,
hoping that this might serve as a biomarker to support the
development of DYRK1B inhibitors. To determine if
DYRK1B could autophosphorylate on other residues, we
analysed potential auto-phosphorylation sites on recombi-
nant DYRK1B by proteolytic digestion and mass
spectrometry (MS). Using a combination of endoproteases
we achieved 85 % coverage of DYRK1B and identified
twelve phosphorylation sites including p-Y63 and p-Y273
that have been previously reported (Supplementary
Table 1). A targeted MS method was developed to quantify
these phosphorylation sites in Cos1 cells expressing Myc-
DYRK1B using multiple reaction monitoring (MRM). This
analysis identified four phosphorylation sites in cells but
only one, S421 in the peptide IpSPLGALQHGFFR, was
inhibited when cells were incubated in the presence of
AZ’294, an early stage precursor of the DYRK1B inhibitor
AZ191 [25] (Table 1). Cellular p-S421 was almost com-
pletely abolished when catalytically inactive DYRK1B
mutants were expressed in Cos1 cells, including the acti-
vation loop mutant DYRK1BY271F/Y273F or the catalytic
lysine mutant DYRK1BK140R (kinase-dead or KD); these
results demonstrated that p-S421 in cells was strongly
dependent on DYRK1B kinase activity (Fig. 1a).
To progress this analysis further a p-S421 phospho-
specific antibody was raised in rabbits and validated by its
ability to detect wild-type DYRK1B but not the non-
phosphorylatable DYRK1BS421A mutant when they were
both expressed in HEK293 cells (Fig. 1b). Treatment of
HEK293 cells with either of two DYRK1B inhibitors,
AZ191 [25] or harmine [36], strongly inhibited p-S421
Table 1 Phosphorylation sites detected by mass spectrometry on both recombinant and cellular DYRK1B and the effect of a DYRK1B inhibitor
on these sites











Yes Yes Yes Noc
Y273
IYQpYIQSR
Yes No Yes Noc
S421
IpSPLGALQHGFFR
Yes Yes Yes Yesc
S531/533/534
THQAPASASSLPGTGAQLPPQPR
Yes Yes Yes Noc
a Data from initial phospho-peptide mapping of recombinant DYRK1B undergoing autophosphorylation in vitro
b Multiple reaction monitoring (MRM) analysis
c The non-phosphorylated peptides corresponding to pS49, pY273, pS421 and pS531/533/534 were detected in the untreated cells
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demonstrating that DYRK1B kinase activity was required
for efficient S421 phosphorylation in cells (Fig. 1c). In
contrast, we have previously shown that these inhibitors do
not inhibit auto-phosphorylation at tyrosine, representing
p-Y273 and p-Y63 [25], demonstrating that at the doses
used they selectively inhibited the Ser/Thr kinase activity
of mature DYRK1B.
Since S421 is located in the DYRK1B kinase domain we
determined if S421 phosphorylation had any role in
DYRK1B kinase activity by comparing wild-type and
DYRK1BS421A in kinase assays. DYRK1B proteins were
expressed in HEK293 cells and isolated by immunopre-
cipitation prior to being assayed for kinase activity in vitro;
kinase activity was normalised to the amount of wild-type
or mutant DYRK1B that was recovered in the immuno-
precipitation. These assays revealed that DYRK1BS421A
exhibited a significant 50 % reduction in intrinsic kinase
activity compared to wild-type DYRK1B (Fig. 1d) whereas
kinase-dead DYRK1BD239A (KD) was completely defec-
tive. However, since only *50 % of DYRK1B was
Fig. 1 S421 is a site of DYRK1B autophosphorylation that contributes
to kinase activity. aWild-type or mutant myc-DYRK1B proteins were
expressed inCOS-1 cells. DYRK1B proteinswere enriched fromwhole
cell lysates using anti-myc antibody. Immuno-complexeswere digested
with trypsin prior to nanoLC-mass spectrometry analysis for relative
phosphorylation of pS421. Error bars show standard deviation
(N = 2). b Empty Vector (EV), Wild-type FLAG-DYRK1B (WT) or
FLAG-DYRK1BS421A (SA) were transiently co-expressed in HEK293
cells for 24 h. Whole cell extracts were separated by SDS-PAGE,
transferred onto PVDF membrane and immuno-blotted with the
antibodies indicated. c Empty vector (EV), kinase-dead (KD, D239A)
or wild-type (WT) FLAG-DYRK1B were transiently co-expressed in
HEK293 cells. 6 h post-transfection, the cells were treated with vehicle
control, 1 lM AZ191 or 1 lM harmine for a further 24 h. Whole cell
extracts were separated by SDS-PAGE, transferred onto PVDF
membrane and immuno-blotted with the antibodies indicated. Data in
b?c are from single experiments representative of five separate
experiments. d FLAG-DYRK1B WT, kinase-dead (KD, D239A) or
S421A proteins were transiently expressed in HEK293 cells for 24 h
and immuno-precipitated from whole cell extracts with an anti-
DYRK1B antibody. The resultant immuno-complexes were divided
into two aliquots. The first aliquot was assayed for kinase activity
against the synthetic substrate peptide Woodtide (50 lM) (upper
panel). The second aliquot was separated by SDS-PAGE gels and
transferred onto PVDF membrane. The amount of DYRK1B protein in
each samplewas determined by quantitative analysis of the immunoblot
using Licor Odyssey (lower panel). DYRK1B kinase activity levels
were normalised to the amount of DYRK1B present in each immuno-
precipitate. Data were averaged from five separate experiments each
with three technical replicates with each bar representing the
mean ± standard deviation. Statistical analysis was performed using
a two-tailed paired t test
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phosphorylated at S421 when over-expressed (Fig. 1a), this
is probably an underestimate of the contribution of S421 to
DYRK1B kinase activity. Thus, S421 phosphorylation
contributes to DYRK1B kinase activity.
DYRK1B autophosphorylation at S421 occurs
in trans
Based on the current model of DYRK activation [4, 7],
DYRK1B autophosphorylation of Y273 is thought to occur
in cis through an intramolecular mechanism. To investigate
if S421 auto-phosphorylation also occurred in cis, we
expressed discrete DYRK1B proteins of different sizes
(using either EGFP-DYRK1B or FLAG-DYRK1B) so that
we could distinguish S421 phosphorylation in cis or in trans
(Fig. 2a). FLAG-DYRK1BD239A (KD) expressed alone was
not phosphorylated on S421, nor was wild-type EGFP-
DYRK1B able to phosphorylate FLAG-DYRK1BS421A
(SA). However, both EGFP- and FLAG-tagged wild-type
DYRK1B auto-phosphorylated on S421, and this was
blocked by AZ191 or harmine. Finally, FLAG-DYRK1BD239A
(KD) was phosphorylated on S421 when co-expressed with
wild-type EGFP-DYRK1B and this was blocked by AZ191
or harmine, suggesting this was an intermolecular phos-
phorylation (Fig. 2a). In addition, we expressed two
different kinase-dead DYRK1B mutants—DYRK1BK140M
or DYRK1BD239A—in HEK293 cells, immunopurified
them and then incubated them in vitro with purified
recombinant GST-DYRK1B; this is a far simpler system
than co-expression in cells (Fig. 2a). These experiments
demonstrated that purified GST-DYRK1B could indeed
phosphorylate the two different kinase-dead DYRK1B
mutants in vitro (Fig. 2b) and in both cases this in vitro
trans-autophosphorylation was abolished by AZ191. Whilst
we cannot rule out the potential involvement of an acces-
sory protein co-purifying with the DYRK1B mutants, these
results strongly suggest that one DYRK1B molecule can
directly phosphorylate another on S421 in vitro. Recombi-
nant GST-DYRK1B was also able to autophosphorylate at
S421 under these conditions and this was again inhibited by
AZ191. In summary, these data strongly suggest that S421
is a novel site of DYRK1B auto-phosphorylation that can
proceed through an in trans mechanism.
Activation of the RAF-MEK-ERK1/2 signalling
pathway also promotes S421 phosphorylation
in cells
In the course of this work we noted that whilst the
DYRK1BS421A mutant was completely defective for
p-S421 in cells (Fig. 1b), ATP-competitive inhibitors of
DYRK1B Ser/Thr kinase activity left some residual p-S421
signal (Fig. 1c), raising the possibility that other cellular
protein kinases might contribute to S421 phosphorylation.
To investigate this we co-expressed DYRK1B together
with an activated KRASG12V mutant because: (i) KRAS
drives activation of multiple protein kinase cascades and
(ii) expression of activated KRAS has previously been
proposed to activate DYRK1B by up to 20-fold [33]. Wild-
type DYRK1B or kinase-dead DYRK1BD239A (KD) was
transiently expressed with KRASG12V for 24 h in HEK293
cells. DYRK1B proteins were then isolated from whole cell
extracts by immunoprecipitation and assayed in an in vitro
DYRK1B kinase assay; activity was again normalised to
the amount of DYRK1B that was recovered in the
immunoprecipitation (Fig. 3a). DYRK1B kinase activity
was increased by co-expression with KRASG12V; however,
this effect was modest and not statistically significant,
reflecting that fact DYRK1B was already very active when
expressed in HEK293 cells. Consistent with this, KRAS
expression also failed to significantly increase S421 phos-
phorylation over the already high basal level (Fig. 3b). As
a control, DYRK1BD239A (KD) exhibited negligible kinase
Fig. 2 S421 autophosphorylation of DYRK1B occurs in trans.
a Wild-type EGFP-DYRK1B was transiently co-expressed in
HEK293 cells along with wild-type (WT), kinase-dead (KD,
D239A) or S421A (SA) FLAG-DYRK1B. 6 h post-transfection, cells
were treated with 1 lM AZ191, 1 lM harmine or vehicle control for
a further 24 h. Whole cell extracts were separated by SDS-PAGE,
transferred onto PVDF membrane and immuno-blotted with the
specified antibodies. All data are taken from a single experiment
representative of three replicate experiments. The asterisk indicates
the position of a non-specific band. b Empty Vector (EV) or kinase-
dead DYRK1B (K140M or D239A) were transfected into HEK293
cells. 24 h post-transfection, DYRK1B proteins were isolated by anti-
FLAG immunoprecipitation and subsequently used as a substrate for
recombinant GST-DYRK1B (wild-type) in an in vitro kinase assay as
describe in ‘‘Materials and methods’’. Terminated assay reactions
were separated by SDS-PAGE and immunoblotted with the indicated
antibodies. Data shown are from a single experiment representative of
three separate experiments with similar results
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activity that was unaffected by KRASG12V expression.
Control blots confirmed that KRASG12V was expressed and
active since it activated endogenous ERK1/2 (Fig. 3b).
During these experiments, we observed that kinase-dead
DYRK1BD239A (KD), which cannot auto-phosphorylate on
S421 (Fig. 1c), became phosphorylated on S421 when co-
expressed with KRASG12V (Fig. 3b). This suggested that
S421 could also be phosphorylated by a kinase other than
DYRK1B in cells and that this kinase was activated by
KRASG12V.
KRAS activates multiple effector pathways including the
RAF-MEK1/2-ERK1/2 pathway and various PI3K-depen-
dent pathways. However, we noted that S421 is immediately
followed by a proline residue (P422) in a Ser-Pro motif, the
minimum required for phosphorylation by proline-directed
kinases such as ERK1/2. To address if activation of the
ERK1/2 pathway alone could increase p-S421,
DYRK1BD239A (KD) was expressed in HR1 cells [39]; these
cells are derived from HEK293 cells and harbour the
DCRAF:ER* fusion protein (Fig. 4a) that is activated by
4-hydroxytamoxifen (4HT). Upon activation of DCRA-
F:ER*, DYRK1BD239A (KD) became phosphorylated on
S421 and this was blocked by the highly selective MEK1/2
inhibitor, selumetinib (AZD6244/ARRY-142886) [40]
(Fig. 4b). To investigate if S421 phosphorylation following
RAF activation also occurred on wild-type DYRK1B, we
used HD1B cells, a cell line that harbours DCRAF:ER* and
exhibits tetracycline-inducible expression of DYRK1B
[25]. When DYRK1B expression was induced with tetra-
cycline, the DYRK1B protein displayed auto-
phosphorylation on S421 (Fig. 4c). Treatment of these cells
with the DYRK1B inhibitor AZ191 blocked p-S421 auto-
phosphorylation but S421 phosphorylation was restored by
DCRAF:ER* activation and this was again blocked by
selumetinib. Thus, activation of the ERK1/2 signalling
pathway was sufficient to drive p-S421 of DYRK1B in cells.
To investigate if other stress-activated, proline-directed
kinases could also promote phosphorylation of S421-
DYRK1B we expressed DYRK1BD239A in HM3 cells;
these are HEK293 cells which harbour an inducible
MEKK3 fusion protein (DMEKK3:ER*) that activates the
ERK1/2, JNK and p38 pathways (Fig. 4a) [41]. Activation
of DMEKK3:ER* with 4HT caused activation of ERK1/2,
JNK1/2 and p38 and increased p-S421 on DYRK1B
(Fig. 4d). However, p-S421 was again blocked by
selumetinib, suggesting that S421-DYRK1B phosphoryla-
tion was mainly dependent on MEK-ERK1/2 activation
and that strong activation of JNK or p38 could not com-
pensate for loss of ERK1/2.
ERK2 directly phosphorylates DYRK1B on S421
in cells and in vitro
If DYRK1B is a direct substrate of ERK1/2 then the
kinetics of S421 phosphorylation on DYRK1B should
closely follow the kinetics of ERK1/2 activation in cells
and should also match the phosphorylation of bona fide
ERK1/2 substrates such as BIMEL [42] and RSK [43]. To
address this we again expressed DYRK1BD239A (KD) in
HR1 cells and stimulated them with 4HT for various times
Fig. 3 KRASG12V promotes S421 phosphorylation. Wild-type or
kinase-dead DYRK1B were transiently expressed together with
empty vector or KRASG12V for 24 h in HEK293 cells. a FLAG-
DYRK1B proteins were isolated from whole cell extracts by
immunoprecipitation and immuno-complexes were divided into two
aliquots. The first aliquot was separated by SDS-PAGE, transferred
onto PVDF membrane and immunoblotted for DYRK1B. DYRK1B
levels were quantified on Licor Odyssey (upper panel). Data are from
a single experiment representative of five separate experiments. The
second aliquot was incubated with the synthetic DYRK substrate
peptide Woodtide in an in vitro kinase assay to determine kinase
activity. In vitro kinase activity was normalised to the amount of
DYRK1B proteins present on the immuno-blot (lower panel). Data in
the graph are presented as mean ± standard deviation from five
separate experiments each with three technical replicates. Statistical
analysis was performed using a two-tailed paired t test. b Whole cell
extracts were fractionated by SDS-PAGE, transferred onto PVDF
membrane and immuno-blotted with the indicated antibodies. Data
are from a single experiment representative of five separate exper-
iments with similar results
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to activate DCRAF:ER*. Activation of ERK1/2 was
observed as early as 15 min after 4HT addition and per-
sisted for the full 120 min timecourse (Fig. 5a). Increases
in p-S421 DYRK1B tracked precisely with p-ERK1/2,
being apparent from 15 min onwards; furthermore, inclu-
sion of selumetinib at each timepoint abolished ERK1/2
activation and the p-S421-DYRK1B signal (Fig. 5a). In
addition, phosphorylation of S421 on DYRK1B precisely
matched the MEK1/2-dependent phosphorylation of RSK
and BIMEL (monitored by it’s characteristic reduction in
mobility on SDS-PAGE) following activation of
DCRAF:ER*.
Fig. 4 Activation of RAF-MEK1/2-ERK1/2 signalling increases
S421-DYRK1B phosphorylation. a Schematic representation of
signalling in HR1 and HM3 cells which express either the
DCRAF:ER* or DMEKK3:ER* fusion proteins that are activated by
4-hydroxytamoxifen (4HT). b Kinase-dead DYRK1BD239A (KD) was
transfected into HR1 cells and DCRAF:ER* was activated by the
addition of 100 nM 4HT in the absence or presence of 1 lM
Selumetinib for a further 24 h. Whole cell lysates were fractionated
by SDS-PAGE, transferred onto PVDF membrane and blotted with
the indicated antibodies. c Wild-type DYRK1B expression was
induced in HD1B cells by the addition of 1 lg ml-1 tetracycline in
the absence or presence of 1 lM AZ191 for 24 h to reduce
autophosphorylation of S421-DYRK1B. In parallel, DCRAF:ER*
was activated by the addition of 100 nM 4-HT in the absence or
presence of 1 lM Selumetinib. d Kinase-dead DYRK1BD239A was
transfected into HM3 cells and DMEKK3:ER* was activated by the
addition of 100 nM 4-HT in the absence or presence of 1 lM
Selumetinib for 24 h. Whole cell lysates were fractionated by SDS-
PAGE, transferred onto PVDF membrane and blotted with the
indicated antibodies. Note that the p-JNK antibody cross reacts with
p-ERK1/2 that is also activated by DMEKK3:ER*. All data is from a
single experiment representative of three separate experiments with
similar results
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To determine if ERK2 could directly phosphorylate
DYRK1B at S421, recombinant, active GST-ERK2 was
incubated with FLAG-DYRK1B in an in vitro kinase assay
(Fig. 5b). In this assay, wild-type DYRK1B was able to
auto-phosphorylate on S421 in the absence of AZ191 (Lane
2) as shown by 32P incorporation and pS421-DYRK1B
western blot. However, 32P was still incorporated into
DYRK1BS421A in the absence of AZ191 (Lane 6), albeit to
a lesser extent than wild-type DYRK1B, suggesting that
there are other sites of DYRK1B auto-phosphorylation
in vitro in addition to S421, consistent with our MS anal-
ysis (Table 1, Supplementary Table 1). In the presence of
AZ191, DYRK1B auto-phosphorylation was blocked
(Lanes 3 and 7). When active ERK2 was added to
DYRK1B in the presence of AZ191, DYRK1B became
phosphorylated on S421 (Lane 4) as shown by 32P incor-
poration and p-S421 western blot and this was blocked by
the ERK1/2 inhibitor SCH772984 [44] (Lane 5) demon-
strating that S421-DYRK1B was a direct substrate of
ERK2 in vitro. Interestingly, ERK2 was also able to
phosphorylate DYRK1BS421A (Lane 8) although to a lesser
degree, indicating that ERK2 may also be able to phos-
phorylate other sites on DYRK1B in vitro. Taken together
these results demonstrated that in addition to auto-phos-
phorylation, DYRK1B is also phosphorylated on S421 by
ERK1/2 in cells and in vitro.
Inhibition of MEK1/2-ERK1/2 signalling
by selumetinib promotes DYRK1B expression
It has previously been show that first generation, pan-
MEK1/2/5 inhibitors PD98059 and U0126 can increase
DYRK1B mRNA and protein [22, 45]. Notwithstanding
the off-target effects of these drugs these results suggest
that ERK1/2 signalling may normally repress DYRK1B
expression. Our demonstration that ERK1/2 phosphorylates
DYRK1B at S421 prompted us to examine DYRK1B
expression using the more selective, second generation
MEK1/2 inhibitor selumetinib [40]. Indeed, when we
treated the melanoma cell line MelJuso (HRASG13D/
NRASQ61L) with 1 lM selumetinib this strongly and
immediately inhibited ERK1/2 signalling and increased the
expression of DYRK1B after a delay of 8 h. This was
accompanied by an increase in DYRK1B mRNA which
was apparent after 5 h of selumetinib treatment (Supple-
mental Fig. 1a). Treatment with actinomycin D, an
inhibitor of transcription, prevented the increase in
DYRK1B expression observed in response to selumetinib
treatment (Supplemental Fig. 1b) suggesting that the
increase in DYRK1B expression observed upon MEK
inhibition reflects de novo gene transcription. Finally,
similar results were obtained in the A375 melanoma cell
line (BRAFV600E) (Supplemental Fig. 1c), where selume-
tinib caused a dose-dependent inhibition of ERK1/2
signalling and an increase in expression of DYRK1B as
well as BIMEL, which is known to be repressed by the
ERK1/2 pathway [46]. Since inhibition of ERK1/2
Fig. 5 S421-DYRK1B is a direct substrate of ERK1/2 in cells and
in vitro. a Kinase-dead DYRK1BD239A (KD) was transfected into
HR1 cells and DCRAF:ER* was activated by the addition of 100 nM
4HT in the absence or presence of 1 lM Selumetinib for 15–120 min.
Whole cell lysates were fractionated by SDS-PAGE, transferred onto
PVDF membrane and blotted with the indicated antibodies. (B)
Empty vector (EV), FLAG-DYRK1B wild-type or FLAG-
DYRK1BS421A were transiently expressed in HEK293 cells. 4 h
post-transfection, cells were treated with 10 lM AZ191 for a further
24 h to minimise DYRK1B autophosphorylation on S421. FLAG-
DYRK1B proteins were then isolated from whole cell extracts by
anti-FLAG immunoprecipitation and the resulting immuno-com-
plexes were washed and used as a substrate in an ERK2 in vitro
kinase assay in the presence of [c-32P]ATP as described in ‘‘Materials
and methods’’. Some of the assay tubes included the ERK1/2 inhibitor
SCH772984. The terminated assay reactions were separated by SDS-
PAGE, transferred onto PVDF membrane and 32P incorporation was
detected by autorad. Subsequently, the membrane was blotted with
the indicated antibodies. Data are from a single experiment
representative of two separate experiments with similar results
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signalling by selumetinib typically causes a G1 cell cycle
arrest [47] (Fig. 6b), the increase in DYRK1B expression
could simply be a consequence of cell cycle arrest rather
than a specific consequence of reduced ERK1/2 signalling.
To address this, we compared the effect of selumetinib with
that of palbociclib (PD-0332991), a potent and highly
selective inhibitor of CDK4 and CDK6 [48]. Whilst both
drugs elicited a strong G1 cell cycle arrest (Fig. 6b) and
inhibited phosphorylation of RB (Fig. 6c), only selumetinib
inhibited ERK1/2 signalling and increased DYRK1B
expression (Fig. 6c), demonstrating that the increase in
DYRK1B was not simply a consequence of cell cycle arrest.
Thus ERK1/2 signalling provides opposing regulatory
inputs into DYRK1B: ERK1/2 can directly phosphorylate
DYRK1B at S421, a residue that promotes kinase activity,
but ERK1/2 signalling also represses DYRK1B expression.
DYRK1B has been proposed to function as a pro-sur-
vival protein kinase [30–32]. Since ERK1/2 inhibition by
selumetinib typically results in a G1 cell cycle arrest with
little cell death [47] we considered the possibility that
DYRK1B expression might provide a survival signal fol-
lowing MEK1/2-ERK1/2 inhibition, thereby preventing
cell death; that is, combined inhibition of MEK1/2 and
DYRK1B would be synthetic lethal. To test this we treated
MelJuso cells with selumetinib alone or in combination
with the DYRK1B inhibitor AZ191 or in combination with
DYRK1B siRNA, with GFP siRNA as a control (Fig. 7a).
AZ191 treatment alone had no effect on cell death as
judged by PARP cleavage (Fig. 7a) and the fraction cells
with hypodiploid (sub-G1) DNA (Fig. 7b). Selumetinib
treatment caused only a small increase in PARP cleavage
and cell death. The combination of AZ191 and selumetinib
caused greater cell death than either drug alone; however,
whilst this was statistically significiant, it was only a very
modest effect. We also observed a modest increase in cell
death when we combined selumetinib with DYRK1B
siRNA; however, this was not statistically significant
(Fig. 7c). Finally, despite the induction of DYRK1B, we
failed to observe any increase in cell death when selume-
tinib was combined with AZ191 or DYRK1B siRNA in
A375 cells (data not shown). Thus, any synthetic lethal
relationship between DYRK1B and MEK1/2 was at best
weak and variable between cell lines.
Mutants of DYRK1B found in cancer or metabolic
syndrome exhibit normal or reduced kinase activity
Systematic sequencing of cancer genomes has revealed rare
mutations in DYRK1B including L28P, R102H, S234G and
Q275R [29]. However, the low incidence of these mutations
calls into question whether they are ‘drivers’ or ‘passen-
gers’ and no further functional information has been
forthcoming. In addition, mutations in DYRK1B have been
found in familial cases of metabolic syndrome [26, 49] and
include: gain-of-function mutations R102C and H90P;
putative loss-of-function mutations, such as L28P, and
apparently benign mutations, such as G352A and P578S.
However, the impact of these disease-associated mutations
Fig. 6 Inhibition of ERK1/2 signalling increases DYRK1B expres-
sion. a MelJuso cells were treated with 1 lM selumetinib for 2–48 h.
Whole cell extracts were fractionated by SDS-PAGE, transferred onto
PVDF membrane and immuno-blotted with the indicated antibodies.
b, cMelJuso cells were treated for 12–48 h with 1 lM Selumetinib or
5 lM Palbociclib and the cells were fixed, stained with propidium
iodide and cell cycle distribution was determined by flow cytometry
(b) and whole cell extracts were fractionated by SDS-PAGE,
transferred onto PVDF membrane and immuno-blotted with the
indicated antibodies (c). Data is from a single experiment represen-
tative of three separate experiments with similar results. The data in
(b) are mean ± S.D. from a single experiment with three replicate
dishes of cell per data point; similar results were obtained in two
additional experiments
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on intrinsic kinase activity has not been described. To
address this directly we engineered some of these mutations
into individual DYRK1B constructs, expressed them in
HEK293 cells, isolated them by immunoprecipitation and
assayed their kinase activity in vitro. Our results revealed a
consistent pattern: DYRK1BL28P (found in rare cases of
metabolic syndrome as well as cancer) exhibited identical
kinase activity to wild-type DYRK1B; DYRK1BR102H and
DYRK1BS234G exhibited 40–50 % reduction in kinase
activity and DYRK1BQ275R exhibited a 90 % reduction in
kinase activity (Fig. 8a). We also directly compared the
activity of the R102H mutant (found in cancer) and the
R102C mutant (found in metabolic syndrome); both
mutants exhibited a 50–60 % reduction in kinase activity
(Fig. 8a). Finally, the relative activity of these DYRK1B
mutants correlated well with their degree of
phosphorylation at S421 (Fig. 8b) suggesting that in the
absence of strong inputs from the ERK1/2 pathway p-S421
correlated well with intrinsic activity. Thus mutations in
DYRK1B that are found in cancer (L28P, R102H, S234G
and Q275R) or metabolic syndrome (L28P, R102C) have
either no effect on intrinsic kinase activity or reduce kinase
activity, in one case (DYRK1BQ275R) severely.
Discussion
Trans-autophosphorylation at S421 contributes
to DYRK1B activity
Our results identified S421 as a site of DYRK1B
autophosphorylation since it was present in purified
Fig. 7 Dual inhibition of ERK1/2 and DYRK1B is not synthetic
lethal. MelJuso cells were transfected with DYRK1B or GFP siRNA
prior to treatment with DMSO, 1 lM selumetinib or 10 lM AZ191
for 48 h. a Whole cell extracts were fractionated by SDS-PAGE,
transferred onto PVDF membrane and immuno-blotted with the
indicated antibodies to confirm inhibition of ERK1/2 signalling and
knockdown of DYRK1B. b MelJuso cells treated for 48 h with
AZ191, selumetinib or the combination were fixed, stained with
propidium iodide and cell cycle distribution determined by flow
cytometry. c MelJuso cells treated for 48 h with DYRK1B siRNA,
selumetinib or the combination were fixed, stained with propidium
iodide and cell cycle distribution determined by flow cytometry. In d,
e data represents mean ± S.D. from four biological replicate
experiments, each with three technical replicates. Statistics were
performed on the population of cells with sub-G1 DNA using one-
way ANOVA, with asterisk denoting p = 0.017 and ns (not
significant) denoting p = 0.167
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recombinant wild-type DYRK1B incubated in vitro with
ATP, absent in kinase-dead DYRK1B and strongly (though
not completely) inhibited by DYRK1B inhibitors in vitro
or in cells. These drugs do not prevent autophosphorylation
on tyrosine (largely Y273, but also Y63) in cells [25]
except at high concentrations [36], consistent with phos-
phorylation of Y273 and S421 proceeding through different
mechanisms. Indeed, we have now shown that S421
autophosphorylation can proceed through an intermolecu-
lar trans-phosphorylation mechanism whereas Y273 is an
intramolecular cis-phosphorylation event. To our knowl-
edge, this is the first description of a serine or threonine
auto-phosphorylation site on DYRK1B. S520 in DYRK1A
was previously identified as a site of auto-phosphorylation
that was required for full DYRK1A kinase activity [18]; in
this case S520 auto-phosphorylation increased 14-3-3b
binding to DYRK1A. However, phosphorylation of S520
in DYRK1A took place in cis, in contrast to the inter-
molecular phosphorylation of S421 in DYRK1B described
here. Indeed, given the position of S421, situated away
from the kinase active site, it is difficult to imagine it could
be phosphorylated in cis through an intramolecular mech-
anism. Regardless, it seems that S421 phosphorylation also
contributes to DYRK1B kinase activity, either directly or
by an indirect mechanism involving accessory proteins,
since the S421A mutant exhibited a consistent 50 %
reduction in kinase activity; indeed, this is likely to be an
underestimate of the impact of the S421A mutant since
only half of over-expressed DYRK1B was phosphorylated
at S421. Whilst a twofold modulation of kinase activity
may seem modest, it is important to remember that even a
50 % increase in expression and activity of the closely
related DYRK1A has profound physiological effects in
mice and phenocopies some Down’s syndrome defects [11,
Fig. 8 DYRK1B mutants found in cancer and metabolic syndrome
exhibit reduced intrinsic kinase activity. a Wild-type DYRK1B or the
indicated mutant DYRK1B constructs were transiently expressed for
24 h in HEK293 cells. FLAG-DYRK1B proteins were isolated from
whole cell extracts by immunoprecipitation and immuno-complexes
were divided into two aliquots. The first aliquot was separated by
SDS-PAGE, transferred onto PVDF membrane and immunoblotted
for DYRK1B (upper panels). DYRK1B levels were quantified on
Licor Odyssey. The second aliquot was incubated with the synthetic
DYRK substrate peptide Woodtide and 0.1 mM [c-32P]ATP in an
in vitro kinase assay to determine kinase activity as described in
materials and methods (lower panel). In vitro kinase activity was
normalised to the amount of each DYRK1B protein present on the
immuno-blot. Data are shown as mean ± standard deviation from
three separate experiments each with three technical replicates. (b)
Wild-type DYRK1B or the indicated mutant DYRK1B constructs
were transiently expressed for 24 h in HEK293 cells. Whole cell
extracts were separated by SDS-PAGE, transferred onto PVDF
membrane and immuno-blotted with the antibodies indicated. Data is
from a single experiment representative of three separate experiments
with similar results
Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity… 895
123
15] whilst a 50 % decrease in DYRK1A causes even more
dramatic effects in Drosophila, mice and human patients
including microcephaly, growth retardation and beha-
vioural defects [11, 50, 51].
S421 occurs close to the highly conserved arginine
residue (AARIS421PL) shortly after alpha helix H/kinase
sub-domain XI [3, 10]. Serine and threonine are the first
and third most common residues at this position across
the kinome as a whole, whilst the Cancer Genome Atlas
(TCGA) reveals that the position equivalent to S421 is
ranked 25th in terms of frequency out of the 2500 iden-
tified mutation positions across kinase domains,
suggesting a potential wider significance for phosphory-
lation at this site. Of the 61 human CMGC kinases listed
at http://kinase.com/human/kinome/groups/cmgc.aln only
7 lack a Ser or Thr at the position corresponding to
Ser421 of DYRK1B. More significantly, S421 in
DYRK1B is a Pro-directed site (Ser-Pro) and within the
closely related human DYRK family (DYRK1A, 1B, 2, 3
& 4 and the four HIPKs) the corresponding site is a Ser-
Pro or Thr-Pro in all cases except DYRK1A (Gln-Pro)
raising the possibility that these kinases may also be
regulated by phosphorylation at this site. This site is also
Ser-Pro or Thr-Pro in DYRKs from lower eukaryotes
including S. pombe Pom1p, S. cerevisiae Yak1p, C. ele-
gans MBK-1 and MBK-2 and D. melanogaster dDYRK2
and dDYRK3, indicating evolutionary conservation of the
site. In terms of functional relevance, intermolecular
phosphorylation at S421 suggests that DYRK1B may be
able to form dimers. Indeed, the structure of the closely
related DYRK1A [10] revealed multiple copies per unit
cell with Q469 of DYRK1A, corresponding to S421 of
DYRK1B, well away from the ATP binding pocket at the
interface between DYRK1A dimers. It is currently unclear
if DYRK1B is a dimer in cells or whether it is more or
less active as a dimer or monomer but it will be inter-
esting to determine if S421 phosphorylation influences
dimerisation. Alternatively, S421 phosphorylation may
influence substrate interactions, which would be consis-
tent with the reduction in kinase activity that we observe
for the S421A mutant. For example, the closely related
DYRK4 exhibits an alternative splicing donor site in exon
19 which removes three amino acids (DCLV) at the end
of the a-helix H, immediately prior to the conserved Arg
in subdomain XI [21]. This region is thought to contribute
to the substrate-binding structure [52] and it is notable
that DYRK4DCLV exhibits reduced kinase activity against
exogenous substrates compared to the full length DYRK4
[21]. Thus, it is possible that changes to this region in
DYRK1B, such as phosphorylation of S421, might con-
tribute to ordering of the substrate-binding structure. Such
speculation will need to be addressed by future structural
studies.
ERK1/2 can phosphorylate DYRK1B at S421
We sought to identify DYRK1B autophosphorylation sites
as biomarkers for DYRK1B kinase activity and identified
S421 as a phosphorylation site that promotes DYRK1B
activity. However, we found that S421 is also phosphory-
lated by ERK1/2; whilst this disqualifies S421 as a unique
DYRK1B activity biomarker it reveals a new mode of
cross talk between ERK1/2 and DYRK1B.
We noted that inhibitors of DYRK1B Ser/Thr kinase
activity left a residual p-S421 signal in cells, prompting a
search for other kinases that might target this site. For this
purpose we co-expressed DYRK1B with KRASG12V, since
KRAS has several effectors (PI3K, RAL, etc.,) and acti-
vates multiple protein kinase signalling pathways. In
contrast to previous reports of a 9- to 20-fold activation
[33] we consistently found that KRASG12V caused only a
very modest (10–15 %) increase in activity that was not
statistically significant. This was not due to a deficit in our
KRAS construct as KRASG12V strongly activated endoge-
nous ERK1/2 in the same transfections. These results
suggest that any effect of activated KRAS on DYRK1B
effector pathways such as Hedgehog [34] may be inde-
pendent of DYRK1B intrinsic kinase activity, though we
cannot rule out a possible effect on DYRK1B substrate
binding (see above) that might be missed in an assay that
employs simplified peptide substrates. However, these
experiments also revealed that KRASG12V could actually
increase DYRK1B phosphorylation at S421. Through a
combination of conditional kinases and selective kinase
inhibitors we were able to show that ERK1/2 activation
alone could increase p-S421, commensurate with estab-
lished ERK1/2 substrates, and ERK2 could phosphorylate
S421 in vitro. This is the first report to clearly define
DYRK1B as a substrate of ERK2. A previous study sug-
gested that ERK2, JNK or p38 might phosphorylate
DYRK1B but stopped short of specifying the kinase,
identifying the phosphorylation site or the effect on
DYRK1B function [53].
Together with previous studies, our results reveal a
complex interplay between ERK1/2 signalling and
DYRK1B. Since phosphorylation of S421 may enhance
DYRK1B kinase activity, ERK1/2 inhibition could
decrease DYRK1B activity. In contrast, previous studies
have indicated that inhibition of ERK1/2 signalling may
increase DYRK1B expression [22, 45] and we also
observed this with the highly selective MEK1/2 inhibitor
selumetinib, suggesting that ERK1/2 signalling can repress
DYRK1B expression. Thus, ERK1/2 inhibition may reduce
the activity of existing DYRK1B but also increase de novo
DYRK1B expression, providing a mechanism for fine
tuning DYRK1B activity. It is well known that the ERK1/2
pathway is a key regulator of the cell cycle, promoting
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proliferation or cell cycle arrest depending on the magni-
tude or duration of ERK1/2 activity [54]. DYRK1A and
DYRK1B have also emerged as regulators of the cell cycle;
both can promote the turnover of CCND1, increase
expression of p21CIP1 and/or p27KIP1 and thereby promote
cell cycle arrest and differentiation [22, 24, 25, 45, 55].
Indeed, even modest (*50 %) changes in DYRK1A
expression and activity exert profound effects on the cell
cycle [56]. ERK1/2-dependent regulation of DYRK1B
adds another level of control, providing a link between two
cell fate signalling pathways.
There is growing interest in identifying synthetic lethal
drug combinations in the treatment of cancer [57]. For
example, whilst selumetinib exerts a largely cytostatic
effect, combining the BH3-mimetic ABT-263 with
selumetinib causes up to 80 % cell death in colorectal cells
and delays the onset of acquired resistance to selumetinib
[47]. The increase in DYRK1B expression following
MEK1/2-ERK1/2 inhibition prompted us to investigate
whether inhibition of DYRK1B might similarly transform
the cytostatic effects of selumetinib to promote cell death.
Indeed, Gao et al. recently described a twofold increase in
H292 cell death when the pan-MEK1/2/5 inhibitor U1026
was combined with DYRK1B siRNA [45], although they
did not report the actual percentage of dead cells. We also
observed a twofold increase in cell death in MelJuso cells
when selumetinib was combined with DYRK1B siRNA or
the AZ191 DYRK1B inhibitor. However, the percentage of
dead cells observed under these conditions was modest,
being less than 20 %, and was not observed in a second cell
line (A375) that exhibited strong DYRK1B upregulation
following ERK1/2 inhibition. Thus, DYRK1B and MEK1/
2 do not seem to exhibit a robust synthetic lethal rela-
tionship that might form the basis for a rational drug
combination.
DYRK1B mutants found in metabolic syndrome
or cancer exhibit normal or reduced kinase activity
DYRK1B is over-expressed due to gene amplification in
certain tumours, including pancreatic cancer [27, 28], and
this has led to the suggestion that DYRK1B is a potential
oncogene. In addition, cancer genome sequencing has
revealed mutations in DYRK1B including L28P, R102H,
S234G and Q275R [29]. Both L28 and R102 lie outside the
DYRK1B kinase domain; L28 lies outside any known
conserved regions whilst R102 is situated between the
DYRK homology (DH) box and the kinase domain. S234 is
conserved in the class 1 DYRKs and immediately precedes
the catalytic loop in kinase subdomain VIb whilst Q275 is
conserved in all DYRKs and follows the critical Y273 in
the kinase activation loop within subdomain VIII. In
addition, L28P and R102C mutations were found in cases
of metabolic syndrome [26, 49]. However, these disease-
associated mutations were found at low frequency and their
impact on DYRK1B activity was not assessed.
We found that these mutations were either neutral with
respect to DYRK1B activity (L28P) or caused a consistent
reduction in kinase activity (R102H, R102C S234G and
Q275R); in the case of the Q275R mutation this effect was
severe, with an approximate 90 % reduction in kinase
activity. Q275 lies within the activation loop of DYRK1B;
whilst activating, oncogenic mutations are found in this
region at significant frequency in some protein kinases,
mutations in this loop, including the introduction of bulky
and highly positive side chain such as arginine, are also
known to inhibit activity by impacting on activation loop
conformation and flexibility. At this stage we cannot rule
out the possibility that these mutations might confer
kinase-independent properties upon DYRK1B; for exam-
ple, by driving DYRK1B to a specific cellular location or
engaging with particular partner proteins. Indeed, some of
the effects of DYRK1B in metabolic syndrome were
apparently independent of DYRK1B kinase activity [26].
Regardless, our results suggest that these DYRK1B muta-
tions are unlikely to be gain-of-function in terms of
intrinsic kinase activity and some may even be loss-of-
function mutations. Since DYRK1B can promote cell cycle
arrest and differentiation [22, 24, 25, 45, 55, 56], such loss-
of-function mutations suggest that any oncogenic proper-
ties of DYRK1B are, at best, context-dependent; indeed,
they may even suggest tumour suppressor functions for
wild-type DYRK1B.
In summary, we demonstrate that phosphorylation of
S421 contributes to DYRK1B kinase activity and that S421
is a site for DYRK1B autophosphorylation and phospho-
rylation by ERK1/2, defining DYRK1B as a new substrate
of ERK1/2. Our results reveal opposing effects of ERK1/2
signalling on DYRK1B which may serve to fine tune
DYRK1B activity. However, despite the ability of ERK1/2
to phosphorylate S421, KRASG12V does not increase
DYRK1B kinase activity. This may be because DYRK1B
expressed in cells is already active so that any effects of
KRAS are modest and incremental; this may require single
cell analysis to resolve. Alternatively, different KRAS
effectors may exert opposing effects on DYRK1B; so
whilst activation of RAF-MEK-ERK may promote S421
phosphorylation, that would enhance activity, other KRAS
effector pathways may exert opposing effects on
DYRK1B. Indeed, our mass spectrometry analysis has
identified at least two other phospho-Ser sites on DYRK1B
expressed in cells that are not autophosphorylation sites;
the kinases for these sites and the functional consequences
remain unknown. Finally, mutants of DYRK1B found in
cancer or metabolic syndrome are either neutral with
respect to kinase activity or exhibit significant decreases in
Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity… 897
123
kinase activity. At least one of these, R102C in metabolic
syndrome, is defined as a gain-of-function mutation [26]
but clearly exhibits reduced kinase activity, raising the
possibility that some effects of DYRK1B may not be
strictly dependent on kinase activity.
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